Stem Cells Quiz: Cell Lineages and Developmental Potential

Totipotent cells can differentiate into any cell type, including all embryonic cells and extraembryonic tissues such as the placenta and yolk sac. The fertilized egg, or zygote, and the cells of the early morula are the classic examples of totipotent cells in mammalian development.

Pluripotent stem cells can differentiate into cells of all three primary germ layers, namely ectoderm, mesoderm, and endoderm, but they cannot form extraembryonic tissues such as the placenta. This ability to form extraembryonic structures is exclusive to totipotent cells.

Embryonic stem cells come from the inner cell mass of the blastocyst, which forms after the morula stage. By this point, cells have lost totipotency because they can no longer form the trophoblast, which gives rise to the placenta. They are pluripotent, capable of forming all three germ layers but not extraembryonic tissue.

Totipotency is found in the zygote and the early blastomeres up to approximately the 8-cell stage in humans. After compaction and differentiation into the inner cell mass and trophoblast, cells become pluripotent or multipotent. Inner cell mass cells and lab-derived embryonic stem cells are pluripotent, not totipotent.

Shinya Yamanaka, along with Kazutoshi Takahashi, demonstrated in 2006 that adult mouse somatic cells could be reprogrammed into a pluripotent state by introducing four transcription factors, now called Yamanaka factors. This landmark discovery earned Yamanaka the Nobel Prize in Physiology or Medicine in 2012.

Hematopoietic stem cells in bone marrow are classified as multipotent, not pluripotent. They can differentiate into multiple types of blood cells, including red blood cells, white blood cells, and platelets, but they cannot give rise to cells of unrelated tissues. Pluripotency refers to the ability to form all three embryonic germ layers.

The four Yamanaka factors used to induce pluripotency in somatic cells are OCT4, SOX2, KLF4, and c-MYC. These transcription factors activate pluripotency-associated genes and silence differentiation-related genes, effectively reprogramming the epigenetic state of the cell back to a stem-cell-like condition.

Multipotent stem cells are restricted to differentiating into a limited range of closely related cell types within a specific tissue or lineage. For example, neural stem cells can form neurons, astrocytes, and oligodendrocytes, but not blood cells. Pluripotent cells have a far broader differentiation potential spanning all germ layers.

Both totipotent and pluripotent cells share the capacity for self-renewal and differentiation into multiple cell types. They also share expression of key pluripotency transcription factors such as OCT4 and NANOG. However, only totipotent cells can form extraembryonic structures like the placenta; this ability is absent in pluripotent cells.

While iPSCs share many functional characteristics with embryonic stem cells, they are not completely identical and do carry risks including tumor formation, as undifferentiated iPSCs can form teratomas in vivo. Epigenetic differences and the use of certain reprogramming factors such as c-MYC, which is a proto-oncogene, also raise safety considerations in therapeutic applications.

The transition from totipotency to pluripotency occurs during blastocyst formation, around days 5 to 6 of human development. As the blastocyst forms, cells of the inner cell mass lose the ability to contribute to the trophoblast lineage, which gives rise to the placenta, and become pluripotent embryonic stem cells.

The defining characteristic that makes totipotent cells more developmentally powerful is their ability to form both the embryo proper and extraembryonic structures including the placenta, amnion, and yolk sac. Pluripotent cells can only form the three embryonic germ layers, making their developmental range more restricted.

Pluripotent stem cells have broad therapeutic potential including growing tissues for transplantation, generating patient-specific iPSC disease models for research, and creating differentiated cell lines for drug screening. Reversing mutations requires gene editing tools such as CRISPR; it is not an inherent property of pluripotent stem cells alone.

The trophoblast, which later forms the placenta and extraembryonic membranes, arises from the outer cells of the compacting morula. These outer cells are still at a totipotent stage of development. Their segregation from the inner cell mass marks the beginning of the first cell fate decision in mammalian embryonic development.

Oligopotent stem cells have an even more restricted differentiation potential than multipotent cells. While multipotent cells can produce a range of related cell types within a lineage, oligopotent cells are limited to producing only two or three specific cell types. An example is the common lymphoid progenitor, which produces only B and T lymphocytes and natural killer cells.